2. Academic Validation
  3. Substituted 1-methyl-4-phenylpyrrolidin-2-ones - Fragment-based design of N-methylpyrrolidone-derived bromodomain inhibitors

Substituted 1-methyl-4-phenylpyrrolidin-2-ones - Fragment-based design of N-methylpyrrolidone-derived bromodomain inhibitors

  • Eur J Med Chem. 2020 Apr 1;191:112120. doi: 10.1016/j.ejmech.2020.112120.
J P Hilton-Proctor 1,  O Ilyichova 1,  Z Zheng 1,  I G Jennings 1,  R W Johnstone 2,  J Shortt 3,  S J Mountford 1,  M J Scanlon 1,  P E Thompson 4
Affiliations

Affiliations

  • 1 Medicinal Chemistry, Monash Institute of Pharmaceutical Sciences, Monash University, 381 Royal Parade, Parkville, Victoria, Australia.
  • 2 Peter MacCallum Cancer Centre, 305 Grattan Street, Melbourne, Victoria, Australia; The Sir Peter MacCallum Department of Oncology, University of Melbourne, Parkville, Victoria, Australia.
  • 3 Blood Cancer Therapeutics Laboratory, School of Clinical Sciences at Monash Health, Monash University, 246 Clayton Road, Clayton, Victoria, Australia; Monash Haematology, Monash Health, 246 Clayton Road, Clayton, Victoria, Australia.
  • 4 Medicinal Chemistry, Monash Institute of Pharmaceutical Sciences, Monash University, 381 Royal Parade, Parkville, Victoria, Australia. Electronic address: [email protected].
PMID: 32120339 DOI: 10.1016/j.ejmech.2020.112120
Abstract

N-Methylpyrrolidone is one of several chemotypes that have been described as a mimetic of acetyl-lysine in the development of bromodomain inhibitors. In this paper, we describe the synthesis of a 4-phenyl substituted analogue - 1-methyl-4-phenylpyrrolidin-2-one - and the use of aryl substitution reactions as a divergent route for derivatives. Ultimately, this has led to structurally complex, chiral compounds with progressively improved affinity as inhibitors of bromodomain-containing protein 4.

Keywords

BRD4; Bromodomain; Epigenetics; Fragment-based Drug Design; K-ac.

Figures
Products